Changes of dipeptidyl peptidase IV (DPP-IV) in obese children with weight loss: Relationships to peptide YY, pancreatic peptide, and insulin sensitivity

Journal of Pediatric Endocrinology and Metabolism

Volumn 23, Issue 1-2, 2010, Pages 101-108

  Reinehr, Thomas ^a   Roth, Christian L ^b   Enriòri, Pablo J ^c,d   Masur, Kai ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Children; DPP IV; Lifestyle intervention; PP; PYY; Weight loss

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GASTROINTESTINAL HORMONE; GLUCOSE; INSULIN; PANCREAS POLYPEPTIDE; PEPTIDE YY;

ANTHROPOMETRY; ARTICLE; BEHAVIOR THERAPY; BODY FAT DISTRIBUTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME MODIFICATION; FEMALE; HEALTH PROGRAM; HORMONE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MALE; NUTRITION EDUCATION; OBESITY; PHYSICAL ACTIVITY; PREPUBERTY; PSYCHOLOGICAL WELL BEING; PUBERTY; REGRESSION ANALYSIS; SCHOOL CHILD; SKINFOLD THICKNESS; WEIGHT REDUCTION;

EID: 77950821251     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2010.23.1-2.101     Document Type: Article

References (40)

1. Wynne K, Stanley S, Bloom S. The gut and regulation of body weight. J Clin Endocrinol Metab 2004; 89: 2576-2582.
2. Murphy KG, Bloom SR. Gut hormones in the control of appetite. Exp Physiol 2004; 89: 507-516.
3. 3. Reinehr T, Enriori PJ, Harz K, Cowley MA, Roth CL. Pancreatic polypeptide in obese children before and after weight loss. Int J Obes 2006; 30: 1476-1481. (Pubitemid 44470194)
4. 4. Lassmann V, Vague P, Vialettes B, Simon MC. Low plasma levels of pancreatic polypeptide in obesity. Diabetes 1980; 29:428-430. (Pubitemid 11018461)
5. 5. Marco J, Zulueta MA, Correas I, Villanueva ML. Reduced pancreatic polypeptide secretion in obese subjects. J Clin Endocrinol Metab 1980; 50: 744-747. (Pubitemid 10009142)
6. 6. Roth CL, Enriori PJ, Harz K, Woelfle J, Cowley MA, Reinehr T. Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J Clin Endocrinol Metab 2005; 90: 6386-6391. (Pubitemid 41759289)
7. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418: 650-654.
8. 8. Alvarez Bartolomé M, Borque M, Martinez-Sarmiento J, Aparicio E, Hernandez C, Cabrerizo L, FernandezRepresa JA. Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 2002; 12: 324-327. (Pubitemid 34621023)
9. 9. Reinehr T, Roth CL, Schernthaner GH, Kopp HP, Kriwanek S, Schernthaner G: Peptide YY and glucagon-like peptide-1 in morbidly obese patients before and after surgically-induced weight loss. Obes Surg 2007; 17: 1571-1577. (Pubitemid 46684364)
10. 10. Naslund E, Gryback P, Hellström PM, Jacobsson H, Hoist JJ, Theodorson E, Backman L. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Dis 1997; 21: 387-392. (Pubitemid 27190191)
11. Mentlein R. Dipeptidyl-peptidase IV (CD26): role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
12. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004; 36: 761-765.
13. 13. Hegen M, Kameoka J, Dong RP, Morimoto C, Schlossman SF. Structure of CD26 (dipeptidyl peptidase IV) and function in human T cell activation. A4v Exp Med Biol 1997; 421: 109-116. (Pubitemid 27432660)
14. 14. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, Liu F, Woods J, Zycband E, Moller DE, Thomberry NA, Zhang BB. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100: 6825-6830. (Pubitemid 36666664)
15. 15. Lugari R, Dei Cas A, Ugolotti D, Barilli AL, Camellini C, Ganzeria GC, Luciani A, Salemi B, Mittenperger F, Nodari S, Gnudi A, Zandomeneghi R. Glucagon-like peptide 1 (GLP-I) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Horm Metab Res 2004; 36: 111-115. (Pubitemid 38392252)
16. 16. Reinehr T, de Sousa G, Toschke M, Andler W. Longterm follow-up of cardiovascular disease risk factors in obese children after intervention. Am J Clin Nutr 2006; 84:490-496. (Pubitemid 44713397)
17. 17. Reinehr T, Andler W. Changes in the atherogenic riskfactor profile according to degree of weight loss. Arch Dis Child 2004; 89:419-422. (Pubitemid 38568553)
18. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320: 1-6.
19. Kromeyer-Hauschild K, Wabitsch M, Geller F, Ziegler A, Geiß HC, Hesse V, v. Hippel A, Jaeger U, Johnsen D, Kiess W, Korte W, Kunze D, Menner K, Müller G, Müller M, Niemann-Pilatus A, Remer Th, Schaefer F, Wittchen HU, Zabransky S, Zellner K, Hebebrand J. Percentiles of body mass index in children and adolescents evaluated from different regional German studies. Monatsschr Kinderheilkd 2001; 149: 807-818.
20. Cole TJ. The LMS method for constructing normalized growth standards. Eur J Clin Nutr 1990; 44:45-60.
21. Slaughter MH, Lohman TG, Boileau RA, Horswill CA, Stillman RJ, Van Loan MD, Bemben DA. Skinfold equations for estimation of body fatness in children and youth. Hum Biol 1988; 60: 709-723.
22. 22. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410. (Pubitemid 32269192)
23. Drent ML, Popp-Snijders C, Ader HJ, Jansen JB, van der Veen EA. Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects. Obes Res 1995; 3: 573-581.
24. 24. Meryn S, Stein D, Straus EW. Fasting- and mealstimulated peptide hormone concentrations before and after gastric surgery for morbid obesity. Metabolism 1986; 35:798-802. (Pubitemid 16025540)
25. 25. Körner J, Inabnet W, Conwell IM, Taveras C, Daud A, Olivero-Rivera L, Restuccia NL, Bessler M. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 2006; 14: 1553-1561. (Pubitemid 46214822)
26. 26. Pfluger PT, Kampe J, Castañeda TR, Vahl T, D'Alessio DA, Kruthaupt T, Benoit SC, Cuntz U, Rochlitz HJ, Moehlig M, Pfeiffer AF, Koebnick C, Weickert MO, Otto B, Spranger J, Tschop MH. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab 2007; 92: 583-588. (Pubitemid 46255299)
27. 27. Miskowiak J, Andersen B, Stadii F, Fahrenkrug J. Meal stimulated levels of pancreatic polypeptide (PP) and vasoactive intestinal polypeptide (VIP) in gastroplasty for morbid obesity. Regul Pept 1985; 12: 231-236. (Pubitemid 16179108)
28. 28. Schrumpf E, Linnestad P, Nygaard K, Giercksky KE, Fausa O Pancreatic polypeptide secretion before and after gastric bypass surgery for morbid obesity. Scand J Gastroenterol 1981; 16: 1009-1014. (Pubitemid 12236118)
29. Druce MR, Small CJ, Bloom SR. Minireview: Gut peptides regulating satiety. Endocrinology 2004; 145: 2660-2665.
30. Meneilly GS, Demuth HU, Mcintosh CH, Pederson RA. Effect of ageing and diabetes on glucosedependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med 2000; 17: 346-350.
31. 31. You T, Yang R, Lyles MF, Gong D, Nicklas BJ. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab 2005; 288: E741-747. (Pubitemid 40397209)
32. 32. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory process in type 2 diabetes: the role of cytokines. Ann NY Acad Sci 2006; 1084: 89-117. (Pubitemid 47091972)
33. 33. Mari A, Sallas WM, He YL, Watson C, LiguerosSaylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894. (Pubitemid 41159387)
34. 34. Bojanowska E. Physiology and pathophysiology of glucagon-like peptide-1 (GLP-1): the role of GLP-I in the pathogenesis of diabetes mellitus, obesity, and stress. Med Sci. Monk 2005; 11: RA271-278. (Pubitemid 41224413)
35. 35. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; ii: 1300-1304. (Pubitemid 17156636)
36. Nauck MA, Wollschlager D, Werner J, Hoist JJ, Orskov C, Creutzfeldt W, Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 39: 1546-1553.
37. th, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993; 361: 362-365.
38. 38. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144:5149-5158. (Pubitemid 37476040)
39. 39. Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, Reeve JR Jr. Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 1994; 51: 151-159. (Pubitemid 2080248)
40. 40. Andersson U, Treebak JT, Nielsen JN, Smith KL, Abbott CR, Small CJ, Carling D, Richter EA. Exercise in rats does not alter hypothalamic AMP-activated protein kinase activity. Biochem Biophys Res Commun 2005; 329: 719-725. (Pubitemid 40311802)